Fzata's vision :  Reduce health inequities by expanding patient access to therapeutic biologics.  Our oral biologics for gastrointestinal (GI) disorders will:

1. improve patient accessibility to biologics with affordable, non-refrigerated, convenient oral capsules

2.  improve patient compliance with no needles and no  health-care administrated infusion

3.  improve patient outcomes given the high safety profile for chronic use

The Fzata proprietary oral Bioengineered Probiotic Yeast Medicines (BioPYM) platform empowers orally administered yeast micro-factories to make biologic therapeutics “on-site” in the gut for treatment of GI diseases.  BioPYM  can target a wide variety of GI disorders like infectious diseases, inflammation, metabolic diseases, (e.g., diabetes), colon cancer, neurodegenerative diseases, and more.  Utilizing BioPYM, we have developed a pipeline of oral biologics to treat GI-related disorders.

​

​